Informa
TIDES Europe: Oligonucleotide and Peptide Therapeutics
2024년 11월 12-14일
CCH - Congress Center Hamburg, Hamburg, Germany

Main Conference Day 2 - CET (Central European Time, GMT+01:00)

Main Conference Day 2 - CET (Central European Time, GMT+01:00)

search
07:30 - 08:0030 mins
Morning Spotlight Presentation: Fluid Air
    08:00 - 08:055 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Chairpersons Remarks: Oligonucleotide Preclinical and Clinical Updates
    • Yogesh Sanghvi, PhD - President, Rasayan Inc.
    08:00 - 08:055 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Chairwoman's Remarks: Case Studies of Innovations and Efficiencies in Oligonucleotide CMC
    • Sonja Merkas, Ph.D. - Founder, Livinovea
    08:00 - 08:055 mins
    Peptide Discovery to CMC
    Chairman’s Remarks: Trends in Peptide Discovery and Synthesis
    • Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
    08:05 - 08:3530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    New Weapons Against Multidrug Resistant Bacterial Infections via an RNA Therapeutics Antibiotic Drug Discovery Platform
    • Peter Nielsen, PhD - Professor, University of Copenhagen
    08:05 - 08:3530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Scaling Up Solution Phase Oligo Manufacturing and Future Innovations
    • Yannick Fillon, PhD - Head of Oligonucleotide Process Chemistry, Biogen
    08:05 - 08:3530 mins
    Peptide Discovery to CMC
    Discovery and Development of Disulfide-constrained Peptides
    • Christina Schroeder, Ph.D. - Senior Fellow, Peptide Therapeutics, Genentech
    08:35 - 09:0530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Using the L-stereoisomer RNA Aptamer NOX-A12 to Enhance Efficacy in Solid Tumors
    • Aram Mangasarian, Ph.D. - Chief Executive Officer, TME Pharma
    08:35 - 09:0530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    .Biocatalytic Approaches to Oligonucleotides Manufacturing, a CMC Perspective
    • Filippo Sladojevich, Ph.D. - Senior Principal Scientist, Hoffmann-La Roche
    08:35 - 09:0530 mins
    Peptide Discovery to CMC
    Development of Membrane-Permeable Cyclic Peptides
    • Christian Heinis, PhD - Associate Professor, Ecole PolyTechnique Federale de Lausanne
    09:05 - 09:3530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Antisense Oligonucleotides for Treatment of Cancer and Kidney Diseases
    • Frank Jaschinski, PhD. - Chief Scientific Officer, Secarna Pharmaceuticals
    09:05 - 09:3530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Designing a Safe, Sustainable, and Efficient Drug Manufacturing Processes for Oligonucleotide Based Products
    • Ashish Garg, Ph.D. - Director, Drug Product Development, Eli Lilly and Company
    09:05 - 09:3530 mins
    Peptide Discovery to CMC
    Targeting Membrane-bound Proteins Using Cell-based Biopanning of Cyclized CLIPS™ Peptides in Phage-displayed Libraries
    • Sheena Ong, PhD - Scientist, Biosynth
    09:35 - 10:1540 mins
    Networking Refreshment Break in Poster and Exhibit Hall
      10:15 - 10:4530 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      RNA Therapies in Heart Failure - An Update
      • Thomas Thum, M.D., Ph.D. - CSO, CMO and Founder, Cardior Pharmaceuticals
      10:15 - 10:4530 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      Plant Design and Manufacturing Challenges with Insights from Leqvio
      • Letizia Volpe, Ph.D. - Site MS&T Head Chemical Operations, Novartis
      10:15 - 10:4530 mins
      Peptide Discovery to CMC
      Development of HER-096 as a Disease Modifying Therapy for Parkinson’s Disease
      • Antti Vuolanto - Chief Executive Officer, Herantis Pharma plc
      10:45 - 11:1530 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      Clinical Update on Rugonersen
      • Erich Koller, Ph.D. - Senior Principal Scientist, Roche Innovation Center Basel
      10:45 - 11:1530 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      NMR Platform Methods for Content and Loop Structure of Oligonucleotides
      • Joan Malmstrøm, Ph.D. - Principal Scientist, CMC Analytical Support, Novo Nordisk A/S
      10:45 - 11:1530 mins
      Peptide Discovery to CMC
      Development of GUBamy, A Clinical Stage Long-acting Amylin Analogue Formulated at Neutral pH, Using StreaMLine - A ML-driven Peptide Drug Discovery Platform
      • Morten Lundh, Ph.D. - Director, Drug Discovery Innovation, Gubra A/S
      11:15 - 11:4530 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      Oligonucleotide IMT504, a Drug Candidate for Complex Regional Pain Syndrome. Preclinical and Phase-I Clinical Results
      • Alejandro Montaner - CEO, Immunalgia Therapeutics
      11:15 - 11:4530 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      Process Development & Manufacturing of Oligos
      • Sonja Merkas, Ph.D. - Founder, Livinovea
      • Yannick Fillon, PhD - Head of Oligonucleotide Process Chemistry, Biogen
      • Filippo Sladojevich, Ph.D. - Senior Principal Scientist, Hoffmann-La Roche
      • Ashish Garg, Ph.D. - Director, Drug Product Development, Eli Lilly and Company
      • Letizia Volpe, Ph.D. - Site MS&T Head Chemical Operations, Novartis
      11:15 - 11:4530 mins
      Peptide Discovery to CMC
      Targeted Innate Immune Stimulators as Therapeutics
      • Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
      11:45 - 11:505 mins
      Transition to Spotlight Presentations
        11:50 - 12:2030 mins
        Spotlight Presentation 1
        Oligo Manufacturing Innovations - From Synthesis through Concentration
        • Tom Krebstakies, PhD - Sales Manager - Europe & Asia, Asahi Kasei Bioprocess
        11:50 - 12:2030 mins
        Spotlight Presentation 2
        Agilent
          11:50 - 12:2030 mins
          Spotlight Presentation 3
          New Trends in Oligotherapeutics
          • Riccardo Bernasconi, Ph.D. - Director Business Development, Bachem
          12:20 - 13:2565 mins
          Networking Luncheon in Poster and Exhibit Hall
          • Kangming Chen, Ph.D. - Head of mRNA & Plasmid Department, GenScript
          • Jiazhen Liang - Senior Scientist, GenScript
          13:25 - 13:5530 mins
          Spotlight Presentation 1
          The Latest Tools for the Characterization of mRNA and Oligonucleotide Biopharmaceuticals by CE and LC-MS
          • Stephen Lock, PhD - Senior Market Development Manager, SCIEX
          13:25 - 13:5530 mins
          Spotlight Presentation 2
          Advancing Oligonucleotide Process Development: Integrating First Principles for Process Characterization
          • Jale Muslehiddinoglu, PhD - Vice President of Strategic Innovation, ST Pharm
          13:25 - 13:5530 mins
          Spotlight Presentation 3
          New LC-MS Approaches for RNA Therapeutics to Ensure Process Consistency and Product Quality
          • Jonathan Fox - Consulting Scientist, Waters Corporation
          13:55 - 14:005 mins
          Oligonucleotide Discovery, Preclinical and Clinical
          Chairman's Remarks: Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical
          • Troels Koch, PhD - Chief Technology Officer, MiNa Therapeutics
          13:55 - 14:005 mins
          Oligonucleotide Chemistry, Manufacturing & Controls
          Chairman's Remarks: Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs
          • Daniel Waschke, Ph.D. - Technical Regulatory Manager, F. Hoffmann-La Roche Ltd.
          13:55 - 14:005 mins
          Peptide Discovery to CMC
          Chairman’s Remarks: Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls
          • Riccardo Bernasconi, Ph.D. - Director Business Development, Bachem
          14:00 - 14:3030 mins
          Oligonucleotide Discovery, Preclinical and Clinical
          Developing RNA Editing As a New Class of Medicine: From Mechanism to Therapeutic Applications
          • Gerard Platenburg, PhD - Chief Scientific Officer, ProQR Therapeutics
          14:00 - 14:3030 mins
          Oligonucleotide Chemistry, Manufacturing & Controls
          An Update on EMA Regulatory Guidelines for Oligonucleotides
          • René Thürmer, PhD - Deputy Head, BfArM Federal Institute for Drugs & Medical Devices
          14:00 - 14:3030 mins
          Peptide Discovery to CMC
          How to Develop a Close-to-commercial Manufacturing Process for Peptide Drug Substance
          • Gajan Santhakumar, Ph.D. - Associate Principal Scientist, Early Chemical Development, AstraZeneca
          14:30 - 15:0030 mins
          Oligonucleotide Discovery, Preclinical and Clinical
          Increasing ASO Stability with Chemical Modifications
          • Erich Koller, Ph.D. - Senior Principal Scientist, Roche Innovation Center Basel
          14:30 - 15:0030 mins
          Oligonucleotide Chemistry, Manufacturing & Controls
          How to Prepare for a Successful IND/IMPD When Developing Oligonucleotide Therapeutics
          • Hagen Cramer, PhD - Chief Technology Officer, QurAlis
          14:30 - 15:0030 mins
          Peptide Discovery to CMC
          Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand
          • Olivier Ludemann-Hombourger, PhD - Director, Global Innovation and Technology, PolyPeptide Group
          15:00 - 15:3030 mins
          Oligonucleotide Discovery, Preclinical and Clinical
          Fatty Acid Conjugation to Enable Oligonucleotide Delivery into the CNS
          • Beatriz Llamusi, PhD - Chief Executive Officer & Co Founder, Arthex Biotech S.L.
          15:00 - 15:3030 mins
          Oligonucleotide Chemistry, Manufacturing & Controls
          General Post-approval Observations and Trends in Oligo Programs from a Regulatory Perspective
          • Tracey Burr, Ph.D. - Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
          15:00 - 15:3030 mins
          Peptide Discovery to CMC
          A Generalized PAT Approach for Fast Peptide Purification Process Development and Production Control in CMC Settings
          • Jörg Kittelmann, Ph.D. - Principal Scientist, CMC Downstream API Development, Novo Nordisk
          15:30 - 16:1545 mins
          Networking Refreshment Break in Poster and Exhibit Hall
          • Sophie Corbet - EMEA Bioprocessing Technical Service Manager, DuPont
          • Mathew Miller, PhD - Director, Life Science and RNA Technologies, Codexis
          16:15 - 16:4530 mins
          Oligonucleotide Discovery, Preclinical and Clinical
          AIC468 - A Novel Antisense Oligonucleotide in Clinical Development for Treatment of BKV Infections
          • Eric van der Veer, PhD - Chief Innovation Officer, Hybridize Therapeutics
          • Holger Zimmermann, PhD - Chief Research & Development Officer, AiCuris Anti-infective Cures
          16:15 - 16:4530 mins
          Oligonucleotide Chemistry, Manufacturing & Controls
          Regulatory CMC Insights on Post-approval Changes for a siRNA Oligonucleotide
          • Daniela Fischer, Ph.D. - Associate Director Regulatory Affairs CMC, Novartis Pharmaceutical Manufacturing
          16:15 - 16:4530 mins
          Peptide Discovery to CMC
          A Second-generation Process for the Manufacturing of Liraglutide
          • Alexander Kleinsmann, PhD - Director R&D, CMC Development, Bachem AG
          16:45 - 17:1530 mins
          Oligonucleotide Discovery, Preclinical and Clinical
          State of the Art siRNA - Delivery and Chemistry
          • Tomaz Einfaltt, Ph.D. - Principal Investigator II xRNA, Novartis Institutes for BioMedical Research
          16:45 - 17:1530 mins
          Oligonucleotide Chemistry, Manufacturing & Controls
          Enzymatic Ligation, Regulatory Challenges and Potential Platform Approaches
          • Sergey Tsukanov, Ph.D. - Senior Director Chemistry, Eli Lilly and Company
          16:45 - 17:1530 mins
          Peptide Discovery to CMC
          Improving Efficiencies in Peptide API Process Development
          • Yi Yang, PhD - Lead Scientist, Ferring Pharmaceuticals A/S
          17:15 - 19:00105 mins
          Evening Networking Reception in Hamburg
            19:00 - 19:055 mins
            Close of Day Two
              Pre-Conference Workshops (am) & Main Conference Day 1 Plenary (pm)
              NextMain Conference Day 3

              * 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.